MX2020010121A - Compuestos con actividad antitumoral contra celulas de cancer que portan las mutaciones del exon 19 del receptor 2 del factor de crecimiento epidermico humano. - Google Patents

Compuestos con actividad antitumoral contra celulas de cancer que portan las mutaciones del exon 19 del receptor 2 del factor de crecimiento epidermico humano.

Info

Publication number
MX2020010121A
MX2020010121A MX2020010121A MX2020010121A MX2020010121A MX 2020010121 A MX2020010121 A MX 2020010121A MX 2020010121 A MX2020010121 A MX 2020010121A MX 2020010121 A MX2020010121 A MX 2020010121A MX 2020010121 A MX2020010121 A MX 2020010121A
Authority
MX
Mexico
Prior art keywords
mutations
compounds
cancer cells
activity against
tumor activity
Prior art date
Application number
MX2020010121A
Other languages
English (en)
Inventor
Jacqulyne Robichaux
John V Heymach
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2020010121A publication Critical patent/MX2020010121A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación proporciona métodos para tratar cáncer en un paciente que tiene una mutación del exón 19 de HER2 tal como una mutación genética, al administrar un inhibidor de tirosina quinasa de tercera generación, tal como poziotinib.
MX2020010121A 2018-03-27 2019-03-27 Compuestos con actividad antitumoral contra celulas de cancer que portan las mutaciones del exon 19 del receptor 2 del factor de crecimiento epidermico humano. MX2020010121A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862648629P 2018-03-27 2018-03-27
US201862688049P 2018-06-21 2018-06-21
PCT/US2019/024353 WO2019191279A2 (en) 2018-03-27 2019-03-27 Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations

Publications (1)

Publication Number Publication Date
MX2020010121A true MX2020010121A (es) 2021-01-08

Family

ID=68060750

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010121A MX2020010121A (es) 2018-03-27 2019-03-27 Compuestos con actividad antitumoral contra celulas de cancer que portan las mutaciones del exon 19 del receptor 2 del factor de crecimiento epidermico humano.

Country Status (14)

Country Link
US (1) US20210361655A1 (es)
EP (1) EP3773551A4 (es)
JP (1) JP7386174B2 (es)
KR (1) KR20200136417A (es)
CN (1) CN112088000A (es)
AU (1) AU2019243738B2 (es)
BR (1) BR112020019251A2 (es)
CA (1) CA3094108A1 (es)
IL (1) IL277373A (es)
MX (1) MX2020010121A (es)
PH (1) PH12020551495A1 (es)
RU (1) RU2020134932A (es)
SG (1) SG11202009498RA (es)
WO (1) WO2019191279A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3121807A1 (en) * 2018-12-21 2020-06-25 Board Of Regents, The University Of Texas System Combination therapy for the treatment of cancer
EP3946293A4 (en) * 2019-03-29 2023-05-03 Board of Regents, The University of Texas System COMPOUNDS WITH ANTITUMORIC ACTIVITIES AGAINST CANCER CELLS WITH EGFR OR HER2 EXON 20 INSERTATIONS
US20220175779A1 (en) * 2019-04-17 2022-06-09 Board Of Regents, The University Of Texas System Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
CA2144319A1 (en) 1993-07-09 1995-01-19 George N. Cox Recombinant ctla4 polypeptides and methods for making the same
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US5869245A (en) 1996-06-05 1999-02-09 Fox Chase Cancer Center Mismatch endonuclease and its use in identifying mutations in targeted polynucleotide strands
US5844905A (en) 1996-07-09 1998-12-01 International Business Machines Corporation Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
US6723564B2 (en) 1998-05-07 2004-04-20 Sequenom, Inc. IR MALDI mass spectrometry of nucleic acids using liquid matrices
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
AU2003233451A1 (en) 2002-03-26 2003-10-13 Massachusetts Institute Of Technology Targets, methods, and reagents for diagnosis and treatment of schizophrenia
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
RU2406760C3 (ru) 2005-05-09 2017-11-28 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
SI2170959T1 (sl) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Protitelesa proti receptorjem pd-1 za humano programirano smrt
BRPI0907718A2 (pt) 2008-02-11 2017-06-13 Curetech Ltd método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
BRPI0917891A2 (pt) 2008-08-25 2015-11-24 Amplimmune Inc antagonistas de pd-1 e métodos de utilização dos mesmos
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Pd−l1/pd−l2の同時阻害
PL2536745T3 (pl) 2010-02-19 2017-01-31 Xencor, Inc. Nowe immunoadhezyny CTLA4-IG
KR101217526B1 (ko) 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
BR112016001420A2 (pt) 2013-08-02 2018-01-23 Aduro Biotech Holdings Europe B V combinação de agonistas de cd27 e inibição pontual imune para estimulação imune
US20180057603A1 (en) * 2013-08-09 2018-03-01 The Trustees Of The University Of Pennsylvania Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers
CA3080200A1 (en) 2013-09-13 2015-03-19 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
EP3230736B1 (en) * 2014-12-12 2020-03-11 Celcuity Inc. Methods of measuring erbb signaling pathway activity to diagnose and treat cancer patients
CA3121807A1 (en) * 2018-12-21 2020-06-25 Board Of Regents, The University Of Texas System Combination therapy for the treatment of cancer

Also Published As

Publication number Publication date
KR20200136417A (ko) 2020-12-07
IL277373A (en) 2020-11-30
WO2019191279A2 (en) 2019-10-03
SG11202009498RA (en) 2020-10-29
CA3094108A1 (en) 2019-10-03
PH12020551495A1 (en) 2021-09-01
RU2020134932A (ru) 2022-04-27
BR112020019251A2 (pt) 2021-01-12
CN112088000A (zh) 2020-12-15
US20210361655A1 (en) 2021-11-25
JP7386174B2 (ja) 2023-11-24
JP2021519306A (ja) 2021-08-10
AU2019243738B2 (en) 2024-05-30
EP3773551A4 (en) 2022-03-23
EP3773551A2 (en) 2021-02-17
WO2019191279A3 (en) 2019-11-07
AU2019243738A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
MX2021011948A (es) Compuestos con actividad antitumoral contra células cancerígenas que llevan inserciones de exon 20 effr o her2.
PH12020551495A1 (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2022012780A (es) Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados.
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
MX2021011209A (es) Novedosos inhibidores de molécula pequeña de factores de transcripción tead.
MX2016010519A (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
MX2021011925A (es) Compuestos con actividad antitumoral contra celulas cancerigenas que portan inserciones del exon 21 del receptor 2 del factor de crecimiento epidermico humano.
MX2017013801A (es) Métodos para tratar el cáncer.
PH12021550119A1 (en) Pyridin-2-one compounds useful as smarca2 antagonists
MY192255A (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
MX2019010149A (es) Inhibicion del smarca2 para el tratamiento del cancer.
MX2021012705A (es) Compuestos con actividad antitumoral contra las celulas cancerosas que portan mutaciones en el receptor del factor de crecimiento epidermico (egfr) resistentes al inhibidor de la tirosina quinasa.
CA2902116C (en) Pyrrolopyridine derivatives and their use as inhibitors of ssao activity
MX2019012176A (es) Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
PH12021551276A1 (en) Combination therapy for the treatment of cancer
PH12017500977A1 (en) 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4h-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
CR20240059A (es) Compuestos tricíclicos como inhibidores de kras.
EA201791179A1 (ru) Дейтерированный триазолопиридазин в качестве модулятора киназы
MX2023006434A (es) Inhibidores de quinasa y usos de los mismos.
MX2018006776A (es) Usos de pirimido-piridazinonas para tratar el cancer.
MX2021003182A (es) Métodos para tratar trastornos mieloproliferativos.
EA201991205A1 (ru) Соединения с противоопухолевой активностью в отношении раковых клеток, несущих мутации в 20 экзоне egfr или her2